Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Non-cryopreserved Kx negative packed red cell concentrates to support hematopoietic stem cell transplantation in McLeod contiguous gene deletion syndrome.

Journal of human immunity·2026
Same author

Progressive short stature in Pearson syndrome and the impact of organ failure.

Molecular genetics and metabolism·2026
Same author

High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia.

Nature genetics·2026
Same author

Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.

Blood advances·2026
Same author

RUNX1-FPDMM in families with mild thrombocytopenia and platelet function anomalies: a case series.

Frontiers in medicine·2025
Same author

Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency.

Blood cancer journal·2025

Video Experimental Relacionado

Updated: Jun 13, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Trasplante de células madre hematopoyéticas: una perspectiva global desde una perspectiva global.

Alois Gratwohl1, Helen Baldomero, Mahmoud Aljurf

  • 1European Group for Blood andMarrow Transplantation, Transplant Activity Survey Office, Department of Hematology, University Hospital Basel, Basel, Switzerland. hematology@uhbs.ch

JAMA
|April 29, 2010
PubMed
Resumen

El trasplante de células madre hematopoyéticas (HSCT) se utiliza en todo el mundo para diversas afecciones. Los países con mayores ingresos, un mayor gasto en atención médica y más equipos de trasplante se correlacionan con mayores tasas de HSCT.

Más Videos Relacionados

Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)
20:38

Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)

Published on: February 25, 2007

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Videos de Experimentos Relacionados

Last Updated: Jun 13, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)
20:38

Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)

Published on: February 25, 2007

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Área de la Ciencia:

  • Hematología Hematología.
  • Medicina de trasplantes Medicina de trasplantes.
  • Salud Global La salud global.

Sus antecedentes:

  • El trasplante de células madre hematopoyéticas (HSCT) es un procedimiento complejo que requiere recursos sustanciales.
  • Los datos mundiales sobre la utilización de HSCT y los factores que influyen siguen siendo limitados.

Objetivo del estudio:

  • Para analizar el uso mundial de HSCT.
  • Identificar las disparidades en la aplicación de HSCT en diferentes regiones.
  • Explorar la relación entre los indicadores macroeconómicos y las tasas de HSCT a nivel mundial.

Principales métodos:

  • Una encuesta retrospectiva de 1327 centros en 71 países en el 2006.
  • Datos recopilados en procedimientos de HSCT alogénicos y autólogos.
  • Análisis de las tasas de trasplante, indicaciones, tipos de donantes y factores macroeconómicos.

Principales resultados:

  • Se realizaron más de 50.000 primeras HSCT, con un 57% autólogo y un 43% alogénico.
  • Las tasas de HSCT variaron significativamente según la región, con Europa mostrando las tasas medianas más altas.
  • La HSCT no se realizó en países con poblaciones por debajo de 300,000, pequeñas áreas de tierra o bajo ingreso nacional bruto per cápita (< $ 680).
  • El gasto público en salud, la densidad del equipo de HSCT, el índice de desarrollo humano y el ingreso nacional bruto per cápita estaban fuertemente asociados con las tasas de HSCT.

Conclusiones:

  • El trasplante de células madre hematopoyéticas se aplica a una amplia gama de enfermedades en todo el mundo.
  • Las naciones de ingresos más altos con sistemas de salud robustos y infraestructura de trasplante establecida utilizan la HSCT con más frecuencia.